PRINCETON, N.J., June 27, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that their annual Investor & Analyst Day, scheduled for Tuesday, June 28, 2016 at 1:30 p.m., will be webcast live.
To access the live webcast, remote individuals can visit www.event.webcasts.com. Full contact information and company affiliation are required to access the webcast. For those still interested in attending in-person in New York City, please register online.
During the event, President and Chief Executive Officer Daniel J. O’Connor will provide opening remarks including a brief synopsis of key milestones achieved throughout the first half of 2016 and goals for the second half of the year. The event will feature presentations from lead investigators from the Company’s clinical trials, including:
- AXAL Cervical Cancer Presentations from Bradley Monk, MD, Warner Huh, MD, Brian Slomovitz, MD
- AXAL Anal Cancer Presentation from Lisa Kachnic, MD
- ADXS-PSA Presentation from Mark Stein, MD
The presentation program and agenda is now available at www.advaxis.com. Full presentation slides and audio will be available for viewing on Wednesday, June 29, 2016 at the same link.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer- fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene filolisbac (AXAL), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted AXAL orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products in human clinical development: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2-expressing solid tumors.
Advaxis Forward-Looking Statement
This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.